TESAMORELIN · DECODED
BY THE NUMBERS
HOW IT WORKS
A stabilized analog of growth hormone-releasing hormone (GHRH). Binds the GHRH receptor on pituitary somatotroph cells, triggering pulsatile GH secretion and downstream IGF-1 elevation. Because the hypothalamic-pituitary feedback loop is preserved, GH release remains physiologically self-regulated, a structural advantage over exogenous synthetic HGH.
WHERE IT CAME FROM
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, the signal the hypothalamus sends to the pituitary gland when it wants growth hormone released into the bloodstream. The hypothalamus is a small region at the base of the brain that acts as the body's master regulator for hormones. The pituitary gland, which sits just below it, receives those signals and acts on them. When the hypothalamus releases GHRH, the pituitary responds by releasing growth hormone in pulses. Tesamorelin mimics that signal precisely. It does not bypass the pituitary. It works through it.
That mechanism matters. Direct growth hormone injection floods the bloodstream with GH all at once, overriding the feedback loop the body uses to keep levels in range. Tesamorelin works with that feedback loop instead. If GH levels rise high enough, the body naturally suppresses further release. The result is a more physiologically normal pattern of GH production. Theratechnologies, a Canadian biopharmaceutical company, developed tesamorelin specifically for a condition called HIV-associated lipodystrophy, an abnormal accumulation of visceral fat, meaning deep abdominal fat around the organs, that occurs in people living with HIV who are on antiretroviral therapy. The FDA approved it under the brand name Egrifta in 2010, making it the first and only FDA-approved treatment for that specific condition.
THE STUDIES
WHAT THE STUDIES SHOW
VISCERAL FAT
- ▸~18% reduction in visceral adipose tissue
- ▸Effect sustained with continued use
- ▸Fat returns when treatment stops
- ▸No meaningful effect on subcutaneous fat
GROWTH HORMONE
- ▸Increases GH in a pulsatile, physiological pattern
- ▸Raises IGF-1 levels (GH downstream marker)
- ▸Preserves natural feedback loop
- ▸Does not suppress endogenous GH production
EMERGING SIGNALS
- ▸Cognitive function improvement in older adults (preliminary)
- ▸Lean mass preservation signals
- ▸Lipid profile improvements in some data
- ▸Further trials needed across non-HIV populations
SIDE EFFECTS
COMMON
- ▸Injection site reactions (redness, itching, pain)
- ▸Fluid retention and peripheral edema
- ▸Joint pain and stiffness
- ▸Muscle aches
- ▸Most are mild and dose-related
NOTABLE / MONITOR FOR
- ▸Elevated blood sugar (GH reduces insulin sensitivity)
- ▸Elevated IGF-1 levels require monitoring (GH downstream marker)
- ▸Caution in patients with active malignancy (GH raises IGF-1, which is growth-promoting)
- ▸Fluid retention can worsen in patients with existing cardiovascular conditions
- ▸Not for use in pregnancy
REGULATORY STATUS
Tesamorelin is FDA approved under the brand name Egrifta, manufactured by Theratechnologies, specifically for the reduction of excess visceral fat in adults with HIV-associated lipodystrophy. That is the only FDA-approved indication. Use outside of that indication, including by people without HIV who want to reduce visceral fat or address age-related growth hormone decline, is off-label. Off-label prescribing is legal and common in medicine. A licensed physician can write a prescription for off-label use, and state-licensed 503A compounding pharmacies can fill that prescription. Compounded tesamorelin is widely available through this pathway. It is not a grey market compound. The prescribing physician takes on the clinical responsibility of supporting the off-label use with appropriate medical judgment.
PROS & CONS
PROS
- +FDA approved, with a Phase 3 human clinical trial record
- +Works through the body's natural GH feedback system rather than overriding it
- +Proven visceral fat reduction in Phase 3 trials
- +Accessible through licensed 503A pharmacies with a physician prescription; no unregulated sourcing required
- +Emerging cognitive benefit data worth watching
- +Longest documented human safety data of any GH secretagogue in this series, built from Phase 3 trials
CONS
- −FDA approval is narrow, HIV lipodystrophy only
- −Daily injection required, no weekly formulation
- −Raises IGF-1, which requires monitoring in anyone with cancer history or risk
- −Visceral fat returns when treatment stops
- −Elevates blood sugar, requires monitoring in pre-diabetic or diabetic patients
- −Off-label use sits in a different risk-benefit calculation than the approved indication
DAILY PEPTIDE VERDICT
RANKING
Tesamorelin has Phase 3 human trial data — the only growth hormone secretagogue in this series that does. The approval is narrow, covering HIV-associated lipodystrophy specifically. The mechanism and the safety data from those trials extend meaningfully to off-label use in visceral fat reduction and age-related GH support, which is how it is most commonly used. The distinction that matters here is evidentiary: the Phase 3 data is real and public, which separates tesamorelin from compounds where the human evidence base is thin, absent, or limited to a single small trial. The emerging cognitive data is genuinely interesting and worth monitoring as the research develops.
DISCLAIMER · EDUCATIONAL USE ONLY
This document is for educational and informational purposes only. Tesamorelin is an FDA-approved pharmaceutical. Prescribing, dosing, and clinical application are the purview of a licensed healthcare provider. Information here synthesizes publicly available clinical data and does not constitute medical advice.